A recombinant rubella virus E1 glycoprotein as a rubella vaccine candidate

Vaccine. 2004 Dec 9;23(4):480-8. doi: 10.1016/j.vaccine.2004.06.030.


A recombinant rubella virus E1 (rE1) glycoprotein was produced and some of its chemical and immunological features were characterized. Two animal models were then used to establish that the rE1 glycoprotein and rubella virus particles shared antigenic and immunogenic properties. In the first one, sera from rE1 glycoprotein-immunized BALB/c mice neutralized in vitro rubella virus infection. In the second model, severe combined immune deficient (SCID) mice implanted with tonsil fragments from rubella immune donors and immunized with rE1 glycoprotein produced human anti-rubella virus antibodies. Altogether, these results showed that immunization with rE1 glycoprotein elicited neutralizing anti-rubella virus antibodies. This study thus indicated that the rE1 glycoprotein could constitute a non-replicating rubella vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Antigens, Viral / administration & dosage
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • Chlorocebus aethiops
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunoglobulin G / blood
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Neutralization Tests
  • Palatine Tonsil / immunology
  • Rubella / immunology
  • Rubella / prevention & control*
  • Rubella Vaccine / administration & dosage
  • Rubella Vaccine / immunology*
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • Vero Cells
  • Viral Envelope Proteins / administration & dosage
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology*


  • Antibodies, Viral
  • Antigens, Viral
  • Immunoglobulin G
  • Rubella Vaccine
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • E1 envelope protein, Rubella virus